Vir Biotechnology, Inc.
VIRNASDAQ
Healthcare
Biotechnology
$9.04
+0.03(0.3%)
52W $4.28 – $10.00
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Revenue breakdown: License And Collaboration Revenue (61.4%), Grant (13.8%), Contract Revenue (12.1%).
$1.4BMkt Cap
$79MRev TTM
-$503MNI TTM
-2.8xP/E TTM
Latest Earnings
10-K
FY FY2025Feb 22, 202610-K for FY2025 was filed on 2026-02-23. AI summary is not available yet.
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
License And Collaboration Revenue61.4%
Grant13.8%
Contract Revenue12.1%
Profit Sharing Amount Previously Constrained Released8.3%
Other4.3%
Revenue by Geography
Non Us73.6%
US26.4%
Company Profile
CIK0001706431
ISINUS92764N1028
CUSIP92764N102
Phone415 906 4324
Address499 Illinois Street, San Francisco, CA, 94158, US
SEC EDGAR